Hyponatremia and thrombocytopenia associated with sorafenib treatment for renal carcinoma: an alert of an adverse event

To date, the manufacturer of sorafenib has reported that the hyponatremia and thrombocytopenia associated with its use are generally moderate and tolerable and have resulted in no mortalities. In this article we describe a Japanese patient with severe hyponatremia and thrombocytopenia that were likely related to sorafenib treatment for metastatic renal carcinoma. Oncologists should be aware of hyponatremia and thrombocytopenia as an adverse effect related to this agent.